Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
PITTSBURGH, Dec. 5, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that its poster focused on CT1812 safety data, its proprietary first-in-class, orally available small molecule in development for the treatment of Alzheimer’s disease, has been selected for presentation at the upcoming the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 8th in San Diego, California.
“We are encouraged that data further supporting the safety profile of CT1812 were chosen for presentation at the CTAD Meeting,” said Kenneth I. Moch, President & CEO of Cognition. “In these Phase 1a clinical studies, CT1812 was found to be safe when administered at multiple dose levels using a once daily, oral dosing schedule for up to two weeks. Building on these data, last month we announced the initiation of our Phase 1b trial in which CT1812 will be dosed daily in individuals with mild to moderate Alzheimer’s disease.”
Cognition’s accepted poster and its presentation time are listed below. Additional information regarding the Clinical Trials on Alzheimer’s Disease meeting can be found online at http://www.ctad-alzheimer.com.
Title of Poster and Presentation Time
CT1812, a drug candidate for Alzheimer’s disease, achieves predicted therapeutic concentrations after multiple dosing in healthy human volunteers
Poster Session 1: Thursday, December 8, 2016 from 8:45 am – 4:30 pm PT
Location: San Diego Ballroom – Lobby Level
Presenter: Michael Grundman, MD, MPH
About CT1812 CT1812 is a proprietary first-in-class, orally available small molecule that displaces bound beta amyloid oligomers and inhibits binding of A? oligomers to the receptor complex. The molecule was designed by Cognition’s scientific team, led by Susan Catalano, Ph.D., to target and displace the toxic beta amyloid oligomers that cause Alzheimer’s disease. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss.
In Cognition’s ongoing Phase 1b Study COG0102, patients with mild to moderate Alzheimer’s disease are being randomized to one of two doses of CT1812 or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Data from this study are expected in mid-2017.
Cognition has previously conducted Phase 1a single and multiple ascending dose studies in 94 healthy volunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc. Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Additional information about Cognition may be found online at http://www.cogrx.com.